Amgen Enters metabolic Disease Market with Biovitrum Deal
By Business Review Editor
Pharma Deals Review: Vol 2003 Issue 40 (Table of Contents)
Published: 3 Oct-2003
DOI: 10.3833/pdr.v2003.i40.860 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Amgen entered into licensing agreement with Biovitrum to acquire rights to Biovitrum’s small molecule 11-beta-HSD1 enzyme inhibitor...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS